Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Clinical trials investigating the newly approved GLP-1RA semaglutide for the treatment of NASH are currently ongoing
About the study The study was published July 9 in the American Journal of Managed Care
For Canadian patients, Ozempic is covered by many provincial formularies for type 2 diabetes, while Retatrutide coverage will depend on Health Canada approval timelines
Flexible financing through Cherry is available for most patients, split into up to 26 monthly payments
Error bars are standard error of the mean
[17] Eli Lilly and Company, 'Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)', ClinicalTrials.gov identifier NCT06260722
US$ 29.09
US$ 29.19
US$ 28.16
US$ 23.86
US$ 27.24
